Editorial companion

What stands out

Bloomberg's Stock Movers captured a neat market contradiction: Moderna is buoyed by US approval of an mRNA flu shot while Intel is tapping public markets with a $15 billion common stock sale, both moves that produced obvious share-price action. Those are not equal signals, one is regulatory validation of a new product, the other is a company leaning on investor appetite as it chases an AI data-center recovery. The episode is useful because it shows how headlines can reshape sentiment faster than quarterly economics do.